A61K 38/1825
Fibroblast growth factor [fgf]
Official title: {Fibroblast growth factor [FGF]}
A61K38/1825 (Fibroblast growth factor [fgf]) appears on 925 US grants and 1,611 published applications in this corpus.
Search patents in A61K- Granted patents
- 925
- Published applications
- 1,611
- Assignees
- 653
- Inventors
- 2,387
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 11 | 0 |
| 1998 | 12 | 0 |
| 1999 | 9 | 0 |
| 2000 | 8 | 0 |
| 2001 | 18 | 5 |
| 2002 | 10 | 31 |
| 2003 | 11 | 37 |
| 2004 | 11 | 47 |
| 2005 | 7 | 57 |
| 2006 | 13 | 57 |
| 2007 | 22 | 45 |
| 2008 | 15 | 75 |
| 2009 | 23 | 56 |
| 2010 | 29 | 60 |
| 2011 | 18 | 76 |
| 2012 | 38 | 54 |
| 2013 | 38 | 95 |
| 2014 | 67 | 97 |
| 2015 | 57 | 97 |
| 2016 | 65 | 77 |
| 2017 | 60 | 91 |
| 2018 | 60 | 79 |
| 2019 | 63 | 81 |
| 2020 | 42 | 74 |
| 2021 | 47 | 70 |
| 2022 | 41 | 74 |
| 2023 | 31 | 45 |
| 2024 | 33 | 61 |
| 2025 | 30 | 46 |
| 2026 | 11 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant fc fusion proteins25 Aug 2026US 12,714,739 B2Novartis AG
- Engineered fibroblast growth factor 1 variants with increased proteolytic stability28 Jul 2026US 12,691,160 B2The Board of Trustees of the Leland Stanford Junior University
- FGF21 compositions for treatment or prevention of neovascularization of the eye and methods therefor16 Jun 2026US 12,653,863 B2Children's Medical Center Corporation
- Recombinant modified fibroblast growth factors and therapeutic uses thereof14 Apr 2026US 12,600,756 B2Trefoil Therapeutics, Inc.
- Allogeneic human plasma and platelet derived products and uses thereof17 Mar 2026US 12,576,109 B2Consano Bio, Inc.
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Neurotrauma treatment1 Oct 2026US 2026/0295016 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Peptide tyrosine-tyrosine analog and use thereof24 Sep 2026US 2026/0285932 A1The United Bio-Technology (Hengqin) Co., Ltd.
- Combination treatments for cholestasis17 Sep 2026US 2026/0272951 A1The Board of Regents of the University of Oklahoma
- Recombinant protein compositions useful for wound healing10 Sep 2026US 2026/0263559 A1Wake Forest University Health Sciences
Most cited
By later US patents
- Renewable neural implant device and method1,456US 5,554,148 ABrown University Research Foundation · 1996
- Three dimensional cell protector/pore architecture formation for bone and tissue constructs778US 7,713,542 B2ADA Foundation · 2010
- Supplemented and unsupplemented tissue sealants, methods of their production and use441US 6,197,325 B1American National Red Cross · 2001
- Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system353US 5,082,670 AThe Regents of the University of California · 1992
- Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone349US 5,270,300 A1993